Mosessian Named one of Top 25 Women Chief Scientific Officers in 2025
Sherly Mosessian, PhD, SOFIE’s Chief Scientific Officer, has been recognized by the […]
![SOFIE Biosciences Prepares Launch of Two [18F]FAPI-74 Phase 3 Studies, following successful FDA engagement](https://sofie.com/wp-content/uploads/2025/09/Graphic_EOP2-PR_News-Post.jpg)
SOFIE Biosciences Prepares Launch of Two [18F]FAPI-74 Phase 3 Studies, following successful FDA engagement
- Favorable End-of-Phase 2 meeting with U.S. FDA for [18F]FAPI-74 for GI cancers
- Primary and […]
Focus on FAPI Newsletter – Fall 2025
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
![[68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial](https://sofie.com/wp-content/uploads/2025/09/image.png)
[68Ga]Ga-API-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial
Kim M Pabst, Manuel M Weber, Christina Laschinsky, Patrick Sandach, Timo Bartel, Alina T Küper, […]
90 Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors
Helena Lanzafame, Christoph E Heilig, Eva Wardelmann, Mélanie Desaulniers, Kim Magaly Pabst, Ilektra Antonia Mavroeidi, […]
Early image acquisition 68Ga-FAPI-46-PET/CT in prone position is promising in the workup of rectosigmoid and anal carcinoma
D Ufton, J Heilinger, H Weis, T Fischer, K Schomäcker, C Bruns, G Dieplinger, H […]
FAPI Symposium at SNMMI Hits its Mark
June 22, 2025 – SOFIE’s fourth FAPI symposium at SNMMI was standing room only, reflecting […]
Focus on FAPI Newsletter – Spring 2025
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
Efficacy of [68Ga]Ga-FAPI-PET as a non-invasive evaluation method of liver fibrosis
Yuriko Mori, Katharina Tamburini, Emil Novruzov, Dominik Schmitt, Eleni Mavriopoulou, Sven H Loosen, Christoph Roderburg, […]